About
mRNA Vaccine Technology
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyVirginia, DC, DE & Maryland
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
1
As Collaborator
1
Total Enrollment
130
By Phase
PHASE1: 2
By Status
RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT03624062Collaborator
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
PHASE1Recruiting
28 participants
Started: Aug 31, 2020 · Completed: Dec 10, 2025
NCT02500680Lead Sponsor
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
PHASE1Unknown
102 participants
Started: Jul 31, 2015 · Completed: Dec 31, 2020
Locations (1)
Headquarters
North Bethesda, MD, United States
Map
Loading map...